New Treatments in Chronic Rhinosinusitis with Nasal Polyps: Expert Insights into the Evidence

/ Print /
| ShareMore
/ Text Size +
4/13/21 12:00 pm EST
Virtual Webinar
United States

This webinar is jointly provided by National Jewish Health.

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Webinar Overview:

Upon completion of this activity, participants should be better able to:

  • Describe clinical features and key concepts in the pathophysiology and immunology of CRSwNP.
  • Evaluate strategies for longitudinal management using a multidisciplinary approach.
  • Discuss current and emerging therapies and treatment selection based on patient inflammatory phenotype, comorbidities and other individual factors.

Target Audience

This activity is designed to meet the educational needs of allergists, otolaryngologists (ENTs), rhinologists, primary care/ family medicine/internal medicine Physicians and Advance Practice Providers (APPs) who diagnose and treat allergic and pulmonary diseases.

Date and Time:

This webinar will be held on:

  • Tuesday, April 6th, 2021 7:00 – 8:15 pm ET
  • Tuesday, April 13th, 2021 12:00 – 1:15 pm ET


Daniel Beswick, MD
Assistant Professor-in-Residence
University of California Los Angeles
Los Angeles, CA
Adjunct Assistant Professor
National Jewish Health
Denver, CO

Eileen Wang, MD, MPH
Assistant Professor
Division of Allergy & Clinical Immunology
Department of Medicine National Jewish Health
Denver, CO


  • Physicians – maximum of 1.25 AMA PRA Category 1 Credit(s)
  • All other health care professionals completing this course will be issued a statement of participation.

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

National Jewish Health designates this live activity for a maximum of 1.25 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

Disclosures of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Education.

Daniel Beswick, MD discloses that he is a consultant for Medtronic.

Eileen Wang, MD, MPH discloses that she is a consultant for AstraZeneca, as well as an investigator for Genentech, GlaxoSmithKline and OPC.

Faculty, Planners and Reviewers: Meghan Brenner, MA; Andrea Harshman, MHA, CHCP, CMP-HC; and Mandy Comeau have no relevant financial relationships to report.

Disclosure of Unlabeled Use

National Jewish Health requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: National Jewish Health at:

Contact this CME provider, National Jewish Health, for privacy policy statement information at: